FDA Grants Priority Review to Priovant’s Brepocitinib for Dermatomyositis
Event summary
- FDA accepted Priovant’s NDA for brepocitinib in dermatomyositis and granted Priority Review, with a PDUFA target action date in Q3 2026.
- Brepocitinib, a dual selective inhibitor of TYK2 and JAK1, showed statistically significant and clinically meaningful improvement in the Phase 3 VALOR study.
- If approved, brepocitinib would be the first targeted therapy for dermatomyositis, addressing a significant unmet medical need.
- Priovant expects to launch brepocitinib in the U.S. at the end of September 2026.
The big picture
Priovant’s brepocitinib represents a potential breakthrough in the treatment of dermatomyositis, a debilitating autoimmune disease with limited therapeutic options. The FDA’s Priority Review designation underscores the significant unmet medical need and the potential of brepocitinib to improve patient outcomes. If approved, brepocitinib could set a new standard for targeted therapies in autoimmune diseases, positioning Priovant as a key player in this space.
What we're watching
- Regulatory Approval
- Whether the FDA will approve brepocitinib by the PDUFA target action date in Q3 2026.
- Market Potential
- The pace at which brepocitinib can capture market share in the dermatomyositis treatment space.
- Clinical Development
- How the success of brepocitinib in dermatomyositis will impact its development in other indications, such as non-infectious uveitis and cutaneous sarcoidosis.
Related topics